This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MALCOLM BLUMENTHAL, MD; RICHARD DAVIS, MD; RICHARD P. DOE, MD

Arch Intern Med. 1965;116(6):819-823.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE PATIENT with unusually severe thyrotoxicosis presents a variety of problems to the physician. He frequently has need for prompt relief from his acute symptomatology. One of the therapeutic agents which has been widely advocated for use in these patients has been reserpine. Canary et al,¹ Lovei and Bona,² Chowdhury,³ and Moncke ⁴ all found that thyrotoxic patients on the whole showed improvement after receiving reserpine. Buchanan et al,⁵ however, observed no improvement in a double blind experiment. Studies in experimental thyrotoxicosis ^5,7 also contradict the value of reserpine.

The first patient on whom we used intramuscular reserpine during severe thyrotoxicosis in 1960 developed a typical carcinoid syndrome ⁸ including bronchial asthma, diarrhea, "flush" of the skin of the face and body, severe tremor, and hallucinations. His symptoms of thyrotoxicosis were not helped but were aggravated. A systematic study of the effects of intramuscular reserpine in thyrotoxicosis has subsequently revealed . . . [Full Text PDF of this Article]

Author Affiliations
MINNEAPOLIS, MINN

From the Metabolic Research Section, Minneapolis Veterans Administration Hospital, and the Department of Medicine, University of Minnesota Medical School, Minneapolis.

Footnotes
Received for publication June 16, 1965; accepted Aug 20.

Reprint requests to Minneapolis Veterans Administration Hospital, Minneapolis, Minn 55417 (Dr. Doe).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?